ArticleMolecular medicine (Cambridge, Mass.)2026
CD4 T-cell platform for delivering interferons as an antiviral countermeasure with a focus on SARS-CoV-2.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Vaccines prevent the incidence of new infections, but availability of interventions that can prevent transition to severe disease is limited. Interferons (IFN) serve an important part of anti-viral host immune defense. Viruses including SARS-CoV-2 dysregulate IFN kinetics, leading to pathogenesis. The efficacy of systemically infused IFNs as a viable antiviral intervention is compromised by their adverse side effects and restrict the acceptable dosage levels. To address this problem, CD4 T cells have been engineered into a cell-based delivery platform that synthesizes antiviral IFNs upon recognizing the envelope protein of SARS-CoV-2. This pathway cannot be disrupted by viruses and delivers the IFNs directly where needed, reducing side effects. Prophylactic and therapeutic effects of the type-I and type-III IFNs, produced from the T-cell delivery platform, on SARS-CoV-2-infected host cells have been determined. Among the tested interferons, type-I IFN-β consistently exhibited the strongest antiviral activity. The platform is based on CD4 T cells engineered with chimeric antigen receptors and can be rapidly re-engineered for targeting any new pathogen with sensitivity toward IFNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.